NCT03326349 (CHRONIC) is a NA clinical trial of Guttmann, NeuroPersonalTrainer in Chronic Stroke, sponsored by Josep M. Tormos Muñoz.

Who is sponsoring NCT03326349?

NCT03326349 is sponsored by Josep M. Tormos Muñoz.

What drugs are being tested in NCT03326349?

Interventions in NCT03326349: Guttmann, NeuroPersonalTrainer, Ictus.online.

What condition does NCT03326349 study?

NCT03326349 studies Chronic Stroke, Cognitive Impairment.

Is NCT03326349 still recruiting?

NCT03326349 is currently completed. Last updated 21 May 2019.

Last reviewed 2019-05-21 · How we verify

NCT03326349: CHRONIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke

Completed NA Last updated 21 May 2019

What this trial tests

NA trial testing Guttmann, NeuroPersonalTrainer in Chronic Stroke in 41 participants. Completed in 7 May 2019.

Timeline

17 October 2017

Primary endpoint
4 February 2019

7 May 2019

Quick facts

Lead sponsor	Josep M. Tormos Muñoz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	41
Start date	17 October 2017
Primary completion	4 February 2019
Estimated completion	7 May 2019
Sites	1 location across Spain

Drugs / interventions tested

Guttmann, NeuroPersonalTrainer
Ictus.online

Conditions studied

Chronic Stroke — all drugs for Chronic Stroke →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Josep M. Tormos Muñoz

Who can join

Adults 18 to 65, any sex, with Chronic Stroke or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of Guttmann NeuroPersonalTrainer (GNPT), a tele-rehabilitation platform developed as a tool for the cognitive rehabilitation of chronic stroke patients. All patients will receive this treatment but in different order: half will receive GNPT and the other half will receive sham cognitive training; after a washout period of three months, crossover will occur and participants from the GNPT condition will receive sham cognitive training, while participants originally from the control intervention will receive GNPT.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cognitive rehabilitation for attention deficits following stroke.
Loetscher T, Potter KJ, Wong D, das Nair R. · · 2019 · cited 68× · PMID 31706263 · DOI 10.1002/14651858.cd002842.pub3
Occupational therapy for cognitive impairment in stroke patients.
Gibson E, Koh CL, Eames S, Bennett S, et al · · 2022 · cited 29× · PMID 35349186 · DOI 10.1002/14651858.cd006430.pub3
A customized home-based computerized cognitive rehabilitation platform for patients with chronic-stage stroke: study protocol for a randomized controlled trial.
Gil-Pagés M, Solana J, Sánchez-Carrión R, Tormos JM, et al · · 2018 · cited 22× · PMID 29566766 · DOI 10.1186/s13063-018-2577-8

Verify or expand the search:

Other recruiting trials for Chronic Stroke

Currently open trials in the same condition.

NCT07468110 — Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke · recruiting
NCT07378774 — Constraint Induced Movement Therapy and Bilateral Training in Chronic Stroke · NA · recruiting
NCT07353203 — Safety and Efficacy of Hip Assist Powered Exoskeleton for Gait Training in Patients With Late Subacute and Chronic Strok · NA · recruiting
NCT07065292 — Plantar Sensation, Position Sense, and Weight-Bearing Asymmetry Related to Balance and Mobility Post-Stroke · recruiting
NCT06286800 — Personalized Transcranial Direct Current Stimulation in Stroke Recovery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03326349 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Josep M. Tormos Muñoz
Last refreshed: 21 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03326349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing